Sleep apnoea syndrome (SAS) is a known risk factor for vascular diseases and stroke. Structural brain damage, manifesting as an overt neurological deficit or more subtly as cognitive dysfunction, is a frequent symptom in SAS. The presence of a biochemical marker of cerebral injury would be of great benefit in SAS to screen for even small brain damage and to monitor efficiacy of therapy.Therefore, in 10 patients with mild SAS (age 50.8±9.9 yrs, respiratory disturbance index (RDI) 18±3.6, lowest arterial oxygen saturation (minSa,O2) 80.5±4.06%) and nine patients with severe SAS (age 50.3±11.5 yrs, RDI 75.4±21.7, minSa,O256.56±14.58%), serum concentrations of neuron-specific enolase (NSE), S‐100β protein, and β‐trace were measured just before and after sleep using commercially available assays.Only serum levels in the normal range could be found, independent of when the blood was taken or the degree of SAS.Structural cerebral injury caused by sleep apnoea syndrome in patients without neurological symptoms or previous cerebrovascular events may be too small to produce a measurable increase in S‐100β, neuron‐specific enolase and β‐trace serum concentrations or subclinical cerebral damage may be outside the lower detection limits of the analytical methods which were used. There is a need for biochemical markers and more sensitive methods for detecting small cerebral injury in sleep apnoea syndrome.
Originating from centres charged with the care of patients with chronic respiratory insufficiency, noninvasive ventilation (NIV) has been used increasingly in chronic and acute respiratory failure during the last decade. Despite a considerable number of series and randomised studies advocating access to NIV for units that treat acute or chronic ventilatory failure, the number of units and the proportion of total ventilatory support remains poor. This is due to lack of education, as many units treat only a few patients per year. Indication, technique, education, monitoring and home care require special experience and a special environment and there is a wide range throughout Europe. With respect to home care in particular, there are many organisations, which range from totally private to hospital based or run for profit. A concerted action, funded by the European Union, will soon provide valuable information about the practice of home ventilation in Europe based on a European survey.